[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598492":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":11,"centralContacts":45,"locations":51,"responsibleParty":89,"collaborators":11,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":11,"eligibilityCriteria":97,"healthyVolunteers":93,"sex":98,"minAge":99,"maxAge":11,"enrollmentInfo":100,"targetDuration":11,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":54,"whyStopped":11,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Animuscure Inc.","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"AMC6156 0.1mg Treatment Group","EXPERIMENTAL",null,[13],"Drug: AMC6156 0.1mg",{"label":15,"type":10,"description":11,"interventionNames":16},"AMC6156 0.3mg Treatment Group",[17],"Drug: AMC6156 0.3mg",{"label":19,"type":10,"description":11,"interventionNames":20},"AMC6156 1.0mg Treatment Group",[21],"Drug: AMC6156 1.0mg",{"label":23,"type":24,"description":11,"interventionNames":25},"Placebo Control Group","PLACEBO_COMPARATOR",[26],"Drug: Placebo",[28,33,37,41],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","AMC6156 0.1mg","Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.",[9],{"type":29,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"AMC6156 0.3mg","Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.",[15],{"type":29,"name":38,"description":39,"armGroupLabels":40,"otherNames":11},"AMC6156 1.0mg","Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.",[19],{"type":29,"name":42,"description":43,"armGroupLabels":44,"otherNames":11},"Placebo","Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.",[23],[46],{"name":47,"role":48,"phone":49,"phoneExt":11,"email":50},"Jooyeon Kim","CONTACT","+82-70-4105-6414","yeoooonee@animuscure.com",[52,65,71,80],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":11,"cosmosGeoPoint":59,"geoPoint":64,"contacts":11},"CHA Bundang Medical Center","RECRUITING","Seongnam-si","Gyeonggi-do","13496","South Korea",{"type":60,"coordinates":61},"Point",[62,63],127.13778,37.43861,{"lat":63,"lon":62},{"facility":66,"status":54,"city":55,"state":56,"zip":67,"country":58,"countryCode":11,"cosmosGeoPoint":68,"geoPoint":70,"contacts":11},"Seoul National University Bundang Hospital","13620",{"type":60,"coordinates":69},[62,63],{"lat":63,"lon":62},{"facility":72,"status":54,"city":73,"state":56,"zip":74,"country":58,"countryCode":11,"cosmosGeoPoint":75,"geoPoint":79,"contacts":11},"Ajou University Hospital","Suwon","16499",{"type":60,"coordinates":76},[77,78],127.00889,37.29111,{"lat":78,"lon":77},{"facility":81,"status":54,"city":82,"state":82,"zip":83,"country":58,"countryCode":11,"cosmosGeoPoint":84,"geoPoint":88,"contacts":11},"Seoul National University Hospital","Seoul","03080",{"type":60,"coordinates":85},[86,87],126.9784,37.566,{"lat":87,"lon":86},{"type":90,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100598492","phase-2-a-study-of-amc6156-in-people-with-sarcopenia-100598492",false,"NCT07072195","A Study of AMC6156 in People With Sarcopenia","A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia","Inclusion Criteria:\n\n* Voluntary participation with written informed consent\n* Male ≥ 65 years or postmenopausal female\n* Diagnosed with sarcopenia:\n* ASM \\\u003C 7.0 kg\u002Fm² (men) or \\\u003C 5.4 kg\u002Fm² (women)\n* Plus low handgrip strength or SPPB ≤ 9\n* MNA screening score ≥ 8\n* Body weight ≥ 35 kg, BMI between 15-30 kg\u002Fm²\n* Willing and able to follow exercise and nutrition guidance\n\nExclusion Criteria:\n\n* Allergy to investigational drug\n* History of GI bleeding, ulcers, or severe liver\u002Fkidney\u002Fheart disease\n* QTc ≥ 450 ms with symptoms\n* Severe COPD, uncontrolled diabetes or thyroid disease\n* Diseases causing cachexia or muscle wasting (e.g., ALS, Parkinson's)\n* Vitamin D deficiency (\\\u003C10 ng\u002FmL), hemoglobin \\\u003C10 g\u002FdL\n* Severe psychiatric disorders or MMSE \\\u003C 21\n* Inability to walk or recent fracture\u002Fsurgery affecting mobility\n* Use of prohibited medications or recent participation in other clinical trials\n* Investigator deems the subject unsuitable for the study","ALL","65 Years",{"count":101,"type":102},80,"ESTIMATED","INTERVENTIONAL",[105],"PHASE2","This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.",[108,109],"Sarcopenia in Elderly","Sarcopenia",[111],"sarcopenia","2026-07-31",{"date":114,"type":115},"2026-08-03","ACTUAL",{"date":117,"type":115},"2025-07-01",{"date":119,"type":102},"2027-02-15",{"name":5,"class":6},4]